DRonabinol Treatment of OSA

Part of paid clinical trials in Chicago, Illinois.

Sponsor
VA Office of Research and Development
Study ID
NCT06477952
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Obstructive Sleep Apnea

Eligibility Criteria

Sex
ALL
Age
N/A - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Dronabinol — DRUG
    Open label Dronabinol treatment for two weeks.

Study Details

This is an open-label trial that tests the effectiveness of Dronabinol in treating obstructive sleep apnea (OSA). All participants will take oral Dronabinol for two weeks. Sleep studies will be conducted before and after treatment to measure OSA severity.

Key Dates

Start date
Aug 25, 2025
Status verified
Sep 2025
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
120 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Single group
    Open label Dronabinol treatment for two weeks.

Primary Outcome Measure

Apnea hypopnea index (AHI) [ Time Frame: 2 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Jesse Brown VA Medical Center, Chicago, ILChicagoIllinois60612
Karen M Lenehan
[email protected]
312-569-6343
Howard S Gordon, MD BS
[email protected]
(312) 569-7331
Bharati Prasad, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Chicago, IL

By research site
Jesse Brown VA Medical Center, Chicago, IL· Chicago, IL

Related Studies